...
首页> 外文期刊>癌と化学療法 >A case of a second cancer of metachronous multiple primary non-small cell lung cancer successfully treated with TS-1 and CDDP chemotherapy
【24h】

A case of a second cancer of metachronous multiple primary non-small cell lung cancer successfully treated with TS-1 and CDDP chemotherapy

机译:TS-1和CDDP化疗成功治疗第二例异源性多原发性非小细胞肺癌第二例癌症

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The patient was a 66-year-old man who had undergone right upper lobectomy and ND 2a systematic lymph node dissection for lung cancer (M/D adenocarcinoma, p-stage IB) in March of 1999 . On November 2003, postoperative routine chest computed tomography(CT) demonstrated a mass in left S6, and pathological diagnosis revealed P/D squamous cell carcinoma (cT1N2M0, stage IIIA) by CT-guided needle biopsy and mediastinoscopy. At first, we tried two courses of a combination chemotherapy consisting of carboplatin (CBDCA) and paclitaxel every 3 weeks. After 2 courses, the regimen was stopped because of grade 3 arthritis. Then, two courses of CBDCA and gemcitabine were performed. The evaluation of the response was SD by the guidelines of Response Evaluation Criteria in Solid Tumor Groups. Next, gefitinib was orally administered for 6 months but the tumor and mediastinal lymph nodes were growing. In January 2005, oral administration of TS-1 (60 mg/1, 2 courses, 75 mg/3-6 courses) was begun twice a day for 21 consecutive days while cisplatin (60 mg/m(2)) was administered intravenously on day 8. The response was PR (the tumor decreased by 46%), no serious adverse effect was observed, and the patient maintained good quality of life throughout the chemotherapy. This case suggests that TS-1+CDDP chemotherapy may be an effective treatment in patients with advanced lung cancer even after many protocols of chemotherapy.
机译:该患者为66岁的男性,于1999年3月接受了右上叶切除术和ND 2a淋巴结清扫术,用于肺癌(M / D腺癌,p期IB)。 2003年11月,术后常规胸部CT扫描显示左S6肿块,并且病理诊断通过CT引导下的穿刺活检和纵隔镜检查发现了P / D鳞状细胞癌(cT1N2M0,IIIA期)。首先,我们每三周尝试两个疗程的联合化疗,包括卡铂(CBDCA)和紫杉醇。经过2个疗程后,由于3级关节炎,该治疗方案被中止。然后,进行了两个疗程的CBDCA和吉西他滨。根据实体瘤组的反应评估标准指南,反应评估为SD。接下来,口服吉非替尼6个月,但肿瘤和纵隔淋巴结却在增长。在2005年1月,开始连续21天每天两次口服TS-1(60 mg / 1,2个疗程,75 mg / 3-6个疗程),而顺铂(60 mg / m(2))则通过静脉注射在第8天,反应为PR(肿瘤减少了46%),未观察到严重的不良反应,并且患者在整个化疗期间维持良好的生活质量。该病例表明,即使在许多化疗方案之后,TS-1 + CDDP化疗也可能是晚期肺癌患者的有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号